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Abstract 
Bronchiectasis unrelated to cystic fibrosis (non-CF bronchiectasis) has become a major respiratory 
disease in developing nations. The dilated mucus filled airways promote bacterial overgrowth 
followed by chronic infection, bronchial inflammation, lung injury and re-infection Accurate 
pathogen identification and antimicrobial susceptibility allowing appropriate treatment, in turn, 
may break this vicious cycle. To study the spectrum and antimicrobial spectrum of pathogen 
yielded from respiratory specimens in adult patients with acute exacerbation of non-cystic fibrosis 
(CF) bronchiectasis. This cross-sectional study was performed at the pulmonology clinics of the 
Aga Khan University, Karachi, Pakistan from 2016-2019. Respiratory specimens were collected 
from adult patients with acute exacerbation of non-CF bronchiectasis presenting in pulmonology 
clinics. Microbial cultures were performed using standard methodology. Susceptibility testing was 
performed and interpreted using Clinical Laboratory Standard Institute criteria.  A total of 345 
positive cultures from 160 patients presenting with acute exacerbation were evaluated. The most 
frequent organisms were Pseudomonas aeruginosa (n=209) followed by Hemophilus influenzae 
(n=40) and Staphylococcus aureus (n=24). High rates of antimicrobial resistance were found in all 
these pathogens. Proportion of Pseudomonas aeruginosa strains resistant to ciprofloxacin, 
imipenem, ceftazidime and piperacillin-tazobactam were 27.1%, 16.8%, 14.8% and 13.1% 
respectively. 65% of Hemophilus influenzae strains were resistant to cotrimoxazole and 
ciprofloxacin and 66.7% of Staphylococcus aureus strains were resistant to methicillin. High 
antimicrobial resistance in non-CF bronchiectasis patients against commonly used antimicrobials 
is a concern and highlight need for urgent community level interventions to improve clinical 
outcome in these patients.  
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Introduction 
Bronchiectasis is a suppurative lung disease which is characterized by inflamed and dilated bronchi 
(1). Bronchiectasis unrelated to cystic fibrosis (non-CF bronchiectasis) has become a major 
primary respiratory disease in developing nations (2). It is a complex disease which gives rise to 
repeated chest infections due to a vicious cycle. The dilated airways filled with mucus promote 
growth of variety of organisms which is followed by chronic infection, bronchial inflammation, 
lung injury and re-infection (3). It is a cause of significant morbidity and mortality in adults and 
has multiple etiologies (e.g. autoimmune disease, cilia abnormalities, obstruction, infectious 
diseases, allergic bronchopulmonary aspergillosis (ABPA), connective tissue disease) and 
phenotypic features (4, 5). The mortality rate ranged from 10% to 16% over a 4-year observation 
period in a study conducted in USA, with culture positive for Pseudomonas aeruginosa  in sputum, 
low BMI, male sex, advanced age and COPD identified as risk factors for mortality (4). Therefore, 
identifying the causative organism and its sensitivity may allow appropriate treatment, in turn, 
breaking the vicious cycle (3).  
Gram negative bacteria are the most frequently seen organisms in the sputum of bronchiectasis 
patients (4). Studies conducted in adult populations of Spain, Greece, Thailand, Australia, UK and 
China identified Haemophilus influenzae and Pseudomonas aeruginosa as the most commonly 
isolated bacteria followed by Streptococcus pneumoniae, Moraxella catarrhalis and 
Staphylococcus aureus (1,5-11).  
India conducted a first of its kind bronchiectasis study in a lower-middle income country in 2019 
that showed P. aeruginosa to be the most common isolated pathogen followed by 
Enterobacteriaceae, S. aureus, M. catarrhalis and H. influenzae highlighting significant variation 
from Europe (12). A cohort study conducted in a tertiary care hospital in Karachi, Pakistan also 
reported P. aeruginosa as the most commonly cultured organism (36.2%) followed by M. 
catarrhalis and H. influenzae (13). 
Exacerbations in non-CF bronchiectasis are a significant cause of morbidity (14). It has been 
hypothesized that the onset might be triggered by a change in airway bacterial composition, or 
spread of same species to new regions of the lung (15). Factors that contribute to pathogenesis of 
bronchiectasis can also cause exacerbations which include neurological disorders, poor nutrition, 
poverty etc. but it is assumed that a pathogen is always involved at some point (2).  
P. aeruginosa has been seen to be the most common pathogen isolated in exacerbations (16,17) 
followed by H. influenzae (18), S. pneumoniae, S. aureus, M. catarrhalis, Escherichia coli and 
Serratia species in that order (14,15). A double-blind randomized control trial in New Zealand in 
2012 also noted a similar trend with H. influenzae being the most common isolated pathogen (19). 
Sputum cultures from patients with bronchiectasis exacerbation, and on treatment in the ICU for 
acute respiratory failure, yielded P. aeruginosa most frequently followed by S. pneumoniae and 
H. influenzae (20).  
In other studies conducted in Spain assessing the bacterial spectrum and antimicrobial resistance 
patterns in exacerbations, P. aeruginosa was noted to be the most common bacterial pathogen 
isolated, followed by S. pneumoniae, H. influenzae, S. aureus and Enterobacteriaceae (21,22). P. 
aeruginosa was also seen to be the most antibiotic resistant organism with isolates being 
ciprofloxacin resistant and multi-drug resistant (not susceptible to at least 1 agent in 3 or more 
antimicrobial classes) (21,22). Many of the S. aureus isolates were also found to be methicillin 
resistant (21,22).  
Little has been published specifically on the spectrum and antibiotic resistance pattern of bacteria 
isolated from sputum cultures of adult patients with exacerbations of non-CF bronchiectasis from 
developing countries. Due to the rampant use of antibiotics, antimicrobial resistance is becoming 
a prominent concern for clinicians around the world, especially in developing countries. One of 
the main culprits for this situation is the ease with which antibiotics can be purchased over the 
counter, and an increased propensity of the clinicians for prescribing antibiotics. Data on spectrum 
of etiology, organisms and resistance in non-CF bronchiectasis is almost non-existent in the 
subcontinent and this study intends to bridge this gap. This  study was conducted to identify the 
microbial agents present in sputum specimen and their resistance pattern in non-CF bronchiectasis 
patients with acute exacerbations. 
 
Materials and Methods 
This was a cross sectional study from the Aga Khan University Hospital (AKUH), Karachi, 
Pakistan (tertiary care hospital) over a 4-year period between 2016 and 2019. Adult patients (>18 
years) diagnosed with non CF bronchiectasis on high resolution CT (HRCT) scan, who presented 
to outpatient pulmonology clinic with acute exacerbation, were included. Patients with a diagnosis 
of cystic fibrosis (CF) (or suspected CF) as well as patients who did not have HRCT scan were 
excluded.An exacerbation of bronchiectasis was defined as a clinical diagnosis by the physician 
when the patient presented with one or more of the following symptoms: uncontrolled cough, 
increased sputum volume, worsened sputum purulence, aggravated dyspnea, fatigue, fever, and 
hemoptysis (23). 
Clinical findings, etiology, microbiological culture of respiratory specimen samples and drug 
susceptibility was recorded on predesigned performa. All microbial cultures were conducted in the 
AKUH laboratory that is accredited with the College of American Physicians (CAP). All 
specimens were processed and reported using CAP standards. Susceptibility testing was performed 
and interpreted using Clinical Laboratory Standard Institute criteria. Sensitivity testing was carried 
out using the agar disc diffusion method. Vancomycin susceptibility testing was reported based on 
minimum inhibitory concentrations.  
The study was approved by Ethical review committee (ERC) of Aga Khan University Hospital 
(ERC # (5097-MED-ERC-17, dated 27th November 2017). 
The data was entered and analyzed using SPSS version 22.0. Baseline characteristics, etiology, 
frequency of isolation in cultures and resistance pattern of organisms were assessed and presented 
in percentages.  
 
Results  
A total of 160 patients who presented to AKUH pulmonology clinics with acute exacerbations of 
non-CF bronchiectasis and fulfilled the inclusion criteria were studied. Dimakou K, 
Triantafillidou C, Toumbis M, et al. Non CF-bronchiectasis: Aetiologic approach, clinical, 
radiological, microbiological and functional profile in 277 patients. Respir Med 2016;116:1-7. 
1. Chang A, Bilton D. Exacerbations in cystic fibrosis: Non-cystic fibrosis bronchiectasis. 
Thorax 2008;63:269-76. 
2. Foweraker J, Wat D.  Microbiology of non-CF bronchiectasis. Eur Respir Mon 2011;52:68-
96. 
3. McShane PJ, Naureckas ET, Tino G, Strek ME. Non–cystic fibrosis bronchiectasis. Am J 
Respir Crit Care Med 2013;188:647-56. 
4. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in 
patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-84. 
5. Angrill J, Agusti C, De Celis R, et al. Bacterial colonisation in patients with bronchiectasis: 
microbiological pattern and risk factors. Thorax 2002;57:15-9. 
6. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult 
bronchiectasis. Respir Med 2007;101:1633-8. 
7. Macfarlane J, McAlinden P, De Soyza A. Longitudinal study of sputum microbiology in adult 
non-CF bronchiectasis. Thorax 2010;65:A177-8. 
8. Palwatwichai A, Chaoprasong C, Vattanathum A, et al.Clinical, laboratory findings and 
microbiologic characterization of bronchiectasis in Thai patients. Respirology 2002;7:63-6. 
9. Olveira C, Padilla A, Martínez-García M-Á, et al. Etiology of bronchiectasis in a cohort of 
2047 patients. An analysis of the Spanish historical bronchiectasis registry. Arch 
Bronconeumol 2017;53:366-74. 
10. Chandrasekaran R, Mac Aogáin M, Chalmers JD, et al. Geographic variation in the aetiology, 
epidemiology and microbiology of bronchiectasis. BMC Pulm Med 2018;18:83. 
11. Dhar R, Singh S, Talwar D, Mohan M, et al. Bronchiectasis in India: results from the European 
Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory 
Research Network of India Registry. Lancet Global Health 2019;7:e1269-e79. 
12. Sharif N, Baig MS, Sharif S, Irfan M. Etiology, clinical, radiological, and microbiological 
profile of patients with non-cystic fibrosis bronchiectasis at a tertiary care hospital of Pakistan. 
Cureus 2020;12:e7208. 
13. Murray MP, Turnbull K, MacQuarrie S, Hill AT. Assessing response to treatment of 
exacerbations of bronchiectasis in adults. Eur Respira J 2009;33:312-8. 
14. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients 
with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care 
Med 2013;187:1118-26. 
15. Finklea JD, Khan G, Thomas S, et al. Predictors of mortality in hospitalized patients with 
acute exacerbation of bronchiectasis. Respir Med 2010;104:816-21. 
16. Gao Y, Guan W, Zhu Y, et al. [Respiratory pathogen spectrum in pulmonary exacerbation of 
bronchiectasis in adults and its association with disease severity].[Article in Chinese]. 
Zhonghua Jie He He Hu Xi Za Zhi 2019;42:254-61. 
17. Guan W-J, Gao Y-H, Xu G, et al. Inflammatory responses, spirometry, and quality of life in 
subjects with bronchiectasis exacerbations. Respir Care 2015;601180-9. 
18. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-
cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled 
trial. Lancet.2012;380:660-7. 
19. Çiftci F, Mülazimoglu DD, Erol S, et al. Effect of sputum bacteriology on the prognosis of 
patients with acute exacerbations of bronchiectasis in the intensive care unit. Eurasian J 
Pulmonol 2018;20:85. 
20. Polverino E, Rosales-Mayor E, Benegas M, et al. Pneumonic and non-pneumonic 
exacerbations in bronchiectasis: clinical and microbiological differences. J Infect 2018;77:99-
106. 
21. Menéndez R, Méndez R, Polverino E, et al. Risk factors for multidrug-resistant pathogens in 
bronchiectasis exacerbations. BMC Infect Dis 2017;17:659. 
22. Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non–cystic fibrosis bronchiectasis in 
adults and its correlation to disease severity. Ann Am Thorac Soc 2015;12:1764-70. 
23. Wilson C, Jones P, O'leary C, et al. Effect of sputum bacteriology on the quality of life of 
patients with bronchiectasis. Eur Respir J 1997;10:1754-60. 
24. Davies G, Wells A, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary 
function in patients with bronchiectasis. Eur Respir J 2006;28:974-9. 
25. Miszkiel KA, Wells AU, Rubens MB, et al. Effects of airway infection by Pseudomonas 
aeruginosa: a computed tomographic study. Thorax 1997;52:260-4. 
26. Loebinger M, Wells A, Hansell D, et al. Mortality in bronchiectasis: a long-term study 
assessing the factors influencing survival. Eur Respir J 2009;34:843-9. 
27. Naing D, Anderios F, Lin Z. Geographic and ethnic distribution of P. knowlesi infection in 
Sabah, Malaysia. Int J Collab Res Inter Med Public Health 2011;3:391-400. 
28. Aslam M, Mirza T, Muhammad A, Sarwat J. Self-medication with antibiotics among 
secondary and tertiary level students in Karachi, Pakistan: A cross sectional study. Inventi 
Rapid: Pharmacy Practice 2013;2013:1-5. 
29. Atif M, Asghar S, Mushtaq I, et al. What drives inappropriate use of antibiotics? A mixed 
methods study from Bahawalpur, Pakistan. Infect Drug Resist 2019;12:687. 
30. Ali I, Khan AU. Self-medication of antibiotics: A perspective on alarming situation in 
Peshawar, Khyber Pakhtunkhwa, Pakistan. Arch Pharmacy Pract 2015;6:68. 
31. Zafar A, Hasan R, Nizamuddin S, et al. Antibiotic susceptibility in Streptococcus pneumoniae, 
Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the 
Survey of Antibiotic Resistance (SOAR) 2002–15. J Antimicrob Chemother 2016;71:i103-9. 
32. Zafar A, Hussain Z, Lomama E, et al. Antibiotic susceptibility of pathogens isolated from 
patients with community-acquired respiratory tract infections in Pakistan--the active study. J 
Ayub Med Coll 2008;20:7. 
33. Ali I, Butt M. Antibiotic susceptibility pattern of bacterial isolates from patients of respiratory 
tract infection at 43 centers in Punjab, Pakistan. Clin Exp Pharmacol 2017;7:229. 
34. Shah SN, Ullah B, Basit A, et al. Prevalence and susceptibility patterns of bacteria causing 





 shows the demographic data of the studied population. Women (56.9%) and the age group >60 
(46.9%) predominated.  
Figure 1 summarizes the etiology of non-CF bronchiectasis in study population. The most common 
etiology seen was Post TB (n=65) which comprised of 40.6% of the sample followed by idiopathic 
(n=50) and ABPA (n=18). 
A total of 345 positive respiratory specimen culture results from 160 patients, in the specified time 
duration, were evaluated. This equates to a mean of 2.2 sputum cultures per patient. A total of 20 
different organisms were isolated from these patients (  
Table 2). The most frequently isolated organisms were P. aeruginosa from 209 samples (60.6%), 
H. influenzae from 40 patients (11.6%), S. aureus from 24 patients (7.0%), Klebsiella pneumoniae 
from 20 patients (5.8%), and S. pneumoniae from 19 patients (5.5%). Relatively rare organisms 
like Aeromonas species, Burkholderia cepacia, Chryseobacterium species, Nocardia species and 
Stenotrophomonas maltophilia were also seen. Twenty-seven (7.8%) cultures had a polymicrobial 
growth. 
Figure 2 shows resistance patterns (including both resistant and intermediately resistant strains) of 
the four most frequently isolated organisms. P. aeruginosa isolates demonstrated highest 
resistance to aztreonam (32.0%) followed by ciprofloxacin (27.1%) and gentamicin (25.6%), while 
44 (21%) of P. aeruginosa isolates were multi-drug resistant (not susceptible to at least 1 agent in 
3 or more antimicrobial classes). H. influenzae isolates showed highest resistance to cotrimoxazole 
(65.0%) and ciprofloxacin (64.1%). S. aureus isolates were all resistant to penicillin (100%), 
followed by levofloxacin (83.3%), erythromycin (75%), gentamicin (50%), cotrimoxazole 
(29.2%), tetracycline (21.7%), clindamycin (20.8%) while 66.7% were categorized as MRSA.  
Vancomycin resistance was not observed. All of K. pneumoniae isolates were resistant to 
ampicillin, and 81.3% of isolates were resistant to cefuroxime followed by ciprofloxacin and 
cotrimoxazole. S. pneumoniae isolates were mostly sensitive to beta lactam but showed highest 
resistance to cotrimoxazole (72.2%) followed by tetracycline (52.9%) and erythromycin (50%).  
 
Discussion 
Our study demonstrated that the majority of the organisms isolated in the respiratory specimens in 
our patients population were gram negative (86%) concordant with the studies conducted in other 
parts of the world (4). P. aeruginosa was by far the most frequently isolated organism (60.6%) 
followed by H. influenzae (11.6%). Gram-positive organisms were less common with S. aureus 
and S. pneumoniae present in 7.0% and 5.5% of the samples respectively. These results are 
consistent with previous studies conducted on patients with bronchiectasis exacerbation 
(16,17,19,21-23). Additionally, a wide range of bacteria were isolated that included rare organisms 
like Aeromonas species, Stenotrophomonas maltophilia and Chryseobacterium species. 
Clinical features, effect on lung function and disease severity vary with different bacteria. P. 
aeruginosa infections have been connected to worse pulmonary function, a greater spread of 
disease (extent of lung involvement), and poor quality of life (24,25). Patients, whose cultures 
grow P. aeruginosa in acute exacerbation of bronchiectasis, are noted to have significantly higher 
number of hospital admissions in an year (20). This is coupled with a greater degree of bronchial 
wall thickening and dilatation, as well as greater degree of small airway disease (26). P. aeruginosa 
colonization has also been seen to be an independent predictor of mortality in bronchiectasis (27). 
This is alarming as a major portion of patients with exacerbation in our study cultured P. 
aeruginosa. This calls for infection control measures to be taken for prevention, as well as 
improved empirical and definitive treatment regimens (27). In addition, H. influenzae has been 
linked to significantly worsened CT scan findings (26). 
P. aeruginosa strains had high resistance to aztreonam, ciprofloxacin and gentamicin. 
Ciprofloxacin resistance (27.1%) in our study was higher than has been observed in a previous 
study (18.4%) (21). 44 (21%) of the P. aeruginosa isolates (12.8% of all specimens) were multi-
drug resistant (not susceptible to at least 1 agent in 3 or more antimicrobial classes). This is slightly 
higher than MDR P. aeruginosa isolates seen in previous studies in which MDR P. aeruginosa 
comprised of 7.9% and 6.6% of samples (21,22). Around two-thirds of the S. aureus isolates in 
our study were methicillin resistant which is twice as high as 25% and 35.3% seen in other studies 
(21,22). This difference in antibiotic resistance can be attributed to unrestricted supply of 
antibiotics in Pakistan (a developing/LMI country), excessive prescription due to patient demand, 
self-medication (28) for conditions that don’t necessarily require antibiotics (flu, cough, abdominal 
pain, skin infections, fever etc.) (29), lack of basic knowledge about antibiotics (that includes 
correct dosage, indications etc.), illiteracy and failure to complete the antibiotic course after 
symptoms subside (30,31).  
H. influenzae isolates showed high resistance to cotrimoxazole (65%) and ciprofloxacin (64.1%). 
K. pneumoniae isolates had high resistance to cefuroxime (81.3%) followed by ciprofloxacin and 
cotrimoxazole. S. pneumoniae isolates showed highest resistance to cotrimoxazole (72.2%) 
followed by tetracycline and erythromycin. Unfortunately, there is lack of data available to 
compare for resistance patterns of these organisms in bronchiectasis exacerbations throughout the 
world. In fact, to our knowledge, this is the first study to describe resistance pattern of all isolated 
organisms in bronchiectasis exacerbation. Antimicrobial resistance of these organisms has been 
studied in Pakistan for other respiratory infections including pneumonia, acute exacerbation of 
chronic bronchitis etc. H. influenzae isolates have been seen to exhibit lower rate of resistance to 
antimicrobials in the past with chloramphenicol and cotrimoxazole being notable exceptions 
(32,33). K. pneumoniae has shown high resistance rates to ampicillin, cotrimoxazole and 
amoxicillin/clavulanic acid (34). High to moderate resistance to cotrimoxazole and erythromycin 
has been seen in S. pneumoniae isolates (32-35). S. aureus has been reported to be highly resistant 
to erythromycin and levofloxacin (34). These reported antimicrobial resistance patterns are 
consistent with the findings of our study.  
Our study covers data from one tertiary care hospital in Pakistan. Since it is a private hospital, the 
patient population belongs to upper-middle class to upper class members of the society. Thus, it is 
not a true representation of the entire population of the city. Moreover, due to its reputation in the 
country, the pulmonology clinics receive relatively complicated cases and therefore the severity 
of disease studied may be different from that seen across the country. The study also covers a 
relatively small sample size of 160 patients.  
 
Conclusions 
P. aeruginosa was the most frequently isolated organism in the respiratory specimens of patients 
diagnosed with an acute exacerbation of non-cystic fibrosis bronchiectasis. 21% of the P. 
aeruginosa strains were multi-drug resistant. High resistance of P. aeruginosa strains to anti-
pseudomonal antimicrobials was noted. This is a source of concern as it is the most frequently 
isolated organism and has been associated with poor prognosis in patients. 
Since this study involves only one tertiary care hospital which caters to only one subset of the 
population, a multicenter country wide study with a larger sample size is needed to further evaluate 
the bacterial etiology and resistance pattern in the population of Pakistan. 
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Table 1: Demographics of bronchiectasis patients. 
Characteristics    Values Range 
Age (years)    N (%)  
18-30 25 (15.6%)  
31-45 32 (20%)  
46-60 28 (17.5%)  
>60 75 (46.9%)  
Age (mean ± SD)     54±19 18-101 
Sex   
Female 91 (56.9%)  
Male   69 (43.1%)  
Female: Male Ratio 1.3:1  
BMI (mean ± SD) 22.03±6.63 14.6- 42.3 
History of Influenza 
Vaccination 
40 (25%)  
Rate of exacerbation 
/year (mean ± SD) 




Table 2: Bacterial species isolated from patients. The culture results were organized by organism 
cultured. 
Organism Frequency (n=345) Percentage (%) 
Pseudomonas aeruginosa 209 60.6 
Hemophilus influenzae 40 11.6 
Staphylococcus aureus 24 7.0 
Klebsiella pneumoniae 20 5.8 
Streptococcus pneumoniae 19 5.5 
Acinetobacter species 12 3.5 
Hemophilus parainfluenzae 12 3.5 
Escherichia coli 11 3.2 
Moraxella catarrhalis 6 1.7 
Serratia species 3 0.9 
Staphylococcus species (not 
aureus) 
3 0.9 
Enterococcus species 2 0.6 
Nocardia asteroides 2 0.6 
Pseudomonas species (not 
aeruginosa) 
2 0.6 
Stenotrophomonas maltophilia 2 0.6 
Aeromonas species 1 0.3 
Burkholderia cepacia 1 0.3 
Chryseobacterium species 1 0.3 
Enterobacter species 1 0.3 




















Figure 2: Antimicrobial resistance (% resistant isolates) in bacteria isolated from respiratory 
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